IL17A and rheumatoid arthritis: Of course, it is not true, since numerous clinical studies confirmed that RA patients failed to exhibit a satisfactory response to neutralization of IL-17/IL-17 receptor (i.e., secukinumab, ixekizumab, and brodalumab) (48–51).